Loading…
Hosted by Scientific Education Support · 🇺🇸 US · EN · 50 episodes
Established thought leaders with verified media credentials.
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
Scientific Education Support hosts Lymphoma Hub, a education show with 50 episodes published.
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas Southwestern Medical
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Susan O’Brien, U
The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in relap
Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in patien
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, What are the key find
During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US.
During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent finding
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sina
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition , December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danil
The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetocl
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Adelba Torres, Hospital Auxilio Mutuo, San Juan, PR. We aske
During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (Gem
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (B
The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-lin
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). The symp
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Lymphoma Hub has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their education audience.
Lymphoma Hub is hosted by Scientific Education Support. The show is categorised under education and has published 50 episodes.
Lymphoma Hub has published 50 episodes.
Lymphoma Hub regularly covers education. It sits in the education category.
Lymphoma Hub is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Lymphoma Hub hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Lymphoma Hub average 12 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Lymphoma Hub's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.